Amneal Pharmaceuticals, Inc. AMRX Biosimilar — Net revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s biosimilar — net revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s biosimilar — net revenue?
- Amneal Pharmaceuticals, Inc. (AMRX) reported biosimilar — net revenue of $22.3M in Q1 2026.
- How has Amneal Pharmaceuticals, Inc.'s biosimilar — net revenue changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s biosimilar — net revenue decreased by 21.9% year-over-year, from $28.54M to $22.3M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s biosimilar — net revenue?
- Over 3 years (2022 to 2025), Amneal Pharmaceuticals, Inc.'s biosimilar — net revenue has grown at a 213.9% compound annual growth rate (CAGR), from $3.24M to $100.23M.
- What does biosimilar — net revenue mean?
- This metric represents the total gross sales of biosimilar pharmaceutical products minus returns, rebates, and other revenue deductions within a specific reporting period. It serves as a key indicator of the company's market penetration and commercial success in the highly regulated, complex biologics space. Tracking this revenue stream helps investors evaluate the growth trajectory and competitive positioning of the company's high-barrier-to-entry product portfolio.